Physician profile
Kari Shearman
NPI 1316633928
$594.33
in general payments reported to CMS, 2019-2025
14 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $48.27 · 2024: $260 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $139.11 | 2023-2025 | Rybrevant, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $80.68 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Tersera Therapeutics LLC | $56.71 | 2025 | Xermelo, Zoladex |
| Daiichi Sankyo INC. | $45.46 | 2024-2025 | Enhertu |
| Adc Therapeutics America, INC. | $43.11 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2025 | Fruzaqla |
| Exelixis INC. | $29.29 | 2025 | Cabometyx |
| Genmab U.S., INC. | $26.04 | 2024 | Epkinly |
| Abbvie INC. | $25.59 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $25.44 | 2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $24.65 | 2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $22.51 | 2024 | Calquence |
| Pharmaessentia USA Corporation | $20.46 | 2025 | Besremi |
| Sumitomo Pharma America, INC. | $19.87 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Shearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.